Galleri Cancer Test Shows Early Gains but No Proven Mortality Benefit Yet
Grail’s $950 Galleri blood test, which screens for dozens of cancers via tumor DNA in the blood, produced mixed results in a UK study of more than 140,000 older adults: adding Galleri to annual screening detected about 937 additional cancers but did not meaningfully reduce late-stage (Stage 3/4) cancers, with a sensitivity around 30% and 2,114 cancers missed after a negative result. Some cancers—like ovarian, myeloma, and esophageal cancers—showed notable early-stage detection gains, but overall mortality benefit remains unproven. The test is not FDA-approved and is available via prescription or telehealth; experts say it could be an add-on to standard care but is not yet a replacement for conventional screening.